The α-glucosidase inhibitor, acarbose, is approved for the treatment of T2DM and is known to reduce postprandial glycaemia [111] through stimulation of GLP-1 [112], and slowing of gastric emptying [105,113]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.